Silver Book Fact

Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.

Kurlan R, Clark S, Shoulson I, Penny J. Economic Impact of Protective Therapy for Early Parkinson’s Disease. Ann Neurol. 1988; 24(1): 153

Reference

Title
Economic Impact of Protective Therapy for Early Parkinson’s Disease
Publication
Ann Neurol
Publication Date
1988
Authors
Kurlan R, Clark S, Shoulson I, Penny J
Volume & Issue
Volume 24, Issue 1
Pages
153

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • Out-of-Pocket Costs, Slowed Progression  
  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $8 billion in 2020–from the…  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • Americans Age 65 and Older with Alzheimer’s Disease, 2010–2050